<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592212</url>
  </required_header>
  <id_info>
    <org_study_id>NI16014</org_study_id>
    <nct_id>NCT03592212</nct_id>
  </id_info>
  <brief_title>Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma</brief_title>
  <acronym>PEGASE2</acronym>
  <official_title>Phosphodiesterase 4 Gene Variant and Salbutamol Response in Persistent Childhood Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate whether the Phosphodiesterase 4 gene variability could
      be implicated in the salbutamol responsiveness in asthmatic children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients from 6 to 18 years old with asthma and receiving a treatment by salbutamol according
      to the usual care will be recruited. Saliva from patients will be collected using Oragen®.DNA
      OG-575 kit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pre- and post-bronchodilator VEMS value</measure>
    <time_frame>Day 0</time_frame>
    <description>comparison of acute response to salbutamol calculated as the percentage difference between the pre- and post-bronchodilator VEMS value (BDR = 100 x [post-VEMS - pre-VEMS]/pre-VEMS) according to the genotype of the rs1504982</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Locating other regions of the PDE4 gene that may be associated with the response to salbutamol by gene mapping (using SNP tags)</measure>
    <time_frame>Day 0</time_frame>
    <description>To identify other SNPs on PDE4 associated with the response (BDR) to salbutamol in childhood asthma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Screening other SNPs (other genes than PDE4) associated with the response to salbutamol in childhood asthma using SNP tags</measure>
    <time_frame>Day 0</time_frame>
    <description>To identify other genes that could be associated with the phenotype of interest (BDR) by tagging other genes.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <description>Measurement of bronchodilator response (BDR)</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva from patients will be collected using Oragen®. DNA OG-575 kit, (DNA Genotek, Kanata,
      Canada) and stored at room temperature.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children 6-18 years old asthmatic patients consulting in the Department of Pediatric
        Pulmonology and Allergy of Necker University Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 6-18 years

          -  Asthma: confirmed asthma symptoms (wheeze, cough, dyspnea, chest tightness) and
             evidence for variable airflow limitation (≥ 12% increase in post bronchodilator FEV1,
             or ≥ 20% decrease in FEV1 post methacholine)

          -  Spirometry prescribed for follow-up

          -  Airflow limitation: FEV1&lt;80% and/or FEV1/FVC &lt;80 pre-bronchodilator

        Exclusion Criteria:

          -  no exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume LEZMI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume LEZMI, MD, PhD</last_name>
    <phone>+33 1 44 49 48 38</phone>
    <email>guillaume.lezmi@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra COLAS</last_name>
    <phone>+33 1 71 19 64 32</phone>
    <email>sandra.colas@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker -Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume LEZMI, MD, PhD</last_name>
      <phone>+33 1 44 49 48 38</phone>
      <email>guillaume.lezmi@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Salbutamol response</keyword>
  <keyword>Phosphodiesterase 4 variant</keyword>
  <keyword>lung function</keyword>
  <keyword>airflow limitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

